Edition:
United States

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

147.89USD
22 Sep 2017
Change (% chg)

$0.11 (+0.07%)
Prev Close
$147.78
Open
$147.76
Day's High
$148.41
Day's Low
$147.03
Volume
74,517
Avg. Vol
148,686
52-wk High
$163.69
52-wk Low
$95.80

Select another date:

Fri, Aug 18 2017

BRIEF-Jazz Pharma announces $500 mln offering of 1.50 pct exchangeable senior notes due 2024

* Jazz Pharmaceuticals Plc - ‍offering of $500 million aggregate principal amount of 1.50% exchangeable senior notes due 2024​

BRIEF-Jazz Pharmac announces offering of $500 mln of exchangeable senior notes

* Jazz Pharmaceuticals announces offering of $500 million of exchangeable senior notes due 2024

BRIEF-Jazz Pharmaceuticals Q2 adjusted earnings per share $2.56

* Jazz Pharmaceuticals announces second quarter 2017 financial results

BRIEF-Jazz Pharmaceuticals announces FDA approval of Vyxeos

* Jazz Pharmaceuticals announces FDA approval of Vyxeos™ (Daunorubicin and Cytarabine) liposome for injection for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)

BRIEF-Jazz Pharmaceuticals and XL-protein GmbH enter into license agreement

* Jazz Pharmaceuticals and XL-protein GmbH enter into a license agreement on PASylation technology to develop long-acting asparaginase product candidates

BRIEF-Jazz Pharmaceuticals says on June 28, its unit entered into pharmacy master services agreement with Express Scripts specialty distribution services

* Jazz Pharmaceuticals says on June 28, its unit entered into a pharmacy master services agreement with express scripts specialty distribution services

BRIEF-Jazz Pharmaceuticals presents data for study of JZP-110 in patients

* Jazz Pharmaceuticals presents data for the phase 3 tones 2 study of JZP-110 in patients with excessive sleepiness associated with narcolepsy

BRIEF-Jazz Pharma to present key data on sleeping disorder drug at meeting

* Jazz pharmaceuticals to present phase 3 data on jzp-110, an investigational treatment for excessive sleepiness in patients with narcolepsy and with obstructive sleep apnea, during 31st annual sleep meeting Source text for Eikon: Further company coverage:

BRIEF-Jazz pharmaceuticals announces Q1 2017 financial results

* Jazz pharmaceuticals announces first quarter 2017 financial results

BRIEF-Jazz Pharmaceuticals announces positive results of JZP-110 study

* Jazz Pharmaceuticals announces positive results from the phase 3 tones 2 study of jzp-110 in narcolepsy patients with excessive sleepiness

Select another date: